Merck gets positive EU CHMP opinions for Keytruda regimens for patients with two types of Gynecologic cancers Ruchika Sharma24 Sept 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
USFDA approves Merck Keytruda plus Carboplatin, Paclitaxel for Primary Advanced or Recurrent Endometrial Carcinoma Ruchika Sharma18 Jun 2024 11:30 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has approved...
Merck announces Phase 3 trial initiations for 4 investigational candidates from its hematology, oncology pipeline Ruchika Sharma6 Jan 2024 12:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of pivotal Phase 3 trials for four of its...
Merck-Eisai endometrial cancer therapy combo fails first-line treatment trial Ruchika Sharma9 Dec 2023 1:30 PM ISTRahway: Merck said on Friday a combination therapy being developed with partner Eisai failed a late-stage trial testing it as a first-line...
Merck, Eisai get Japanese nod for cancer cocktail drug Keytruda, Lenvima Ruchika Sharma30 Dec 2021 12:22 PM ISTKenilworth: Merck, known as MSD outside the United States and Canada, and Eisai have announced that the Japanese Ministry of Health, Labour and...
